Marjan V. D.
- Country
- The Netherlands
- Department
- Oncology
Research Overview
- Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant Therapy
- Phase III Multicenter Randomized Trial of Dose-Reduced Chemotherapy with Fluorouracil, Folinic Acid, Capecitabine, and Oxaliplatin in Metastatic Colorectal Cancer
- Evaluation of Image-Guided De-Escalation of Neoadjuvant Chemotherapy with Trastuzumab, Pertuzumab, and Drug Combination in HER2-Positive Breast Cancer
Data & Insights
Has run more than one trial at 68 of 148 partner sites.
Specializations
Breast Cancer Treatment Innovation
The investigator specializes in developing advanced therapeutic approaches for hormone receptor-positive breast cancer, with particular emphasis on HER2-positive breast cancer management.
- Neoadjuvant Chemotherapy Optimization
- Dual HER2-blockade Therapies
- Image-guided Treatment Strategies
Key focus includes innovative approaches to chemotherapy de-escalation and targeted therapeutic interventions.
Endocrine Therapy Research
Expertise extends to hormone therapy optimization and the investigation of CDK4/6 inhibition strategies for advanced breast cancer treatment.
- First-line Treatment Strategies
- Aromatase Inhibitor Combinations
- Vasomotor Symptoms Management
Research encompasses novel therapeutic combinations and sequential treatment approaches.
Lung Cancer Therapeutics
The investigator studies innovative approaches in advanced non-small cell lung cancer (NSCLC) treatment, focusing on immunotherapy optimization.
- Immunotherapy Dose Optimization
- Cost-effective Treatment Strategies
- Advanced Stage NSCLC Management
Investigates treatment efficacy while considering cost-effectiveness and optimal dosing strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.